Chromocell Therapeutics Corporation (CHRO) News

Chromocell to Participate in the Virtual Investor Lunch Break Series

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024

FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the...

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the...

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the...

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the...

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the...

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in...

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO...

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO...